Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Total Liabilities
Everything the company owes to creditors and other parties.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 375.0% from a year ago
Total liabilities stood at $1.69M at the end of Q1 FY2026, up 375.0% from a year earlier and down 4.8% from the prior quarter. Over 3 fiscal years it compounded at +64.8% a year.
Context
- Total liabilities amounted to 15.5% of total assets at the end of Q1 FY2026, down 7.9 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +375.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.77M USD
- Year-over-year change
- +456.8%
- 4-year CAGR
- +55.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.77M | +456.8% |
| FY2024 | 2024-12-31 | 318.28K | +1.4% |
| FY2023 | 2023-12-31 | 313.86K | -20.7% |
| FY2022 | 2022-12-31 | 395.76K | +30.6% |
| FY2021 | 2021-12-31 | 302.93K | — |
Total Liabilities vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 total liabilities of $1.69M is the lowest of the 2 companies compared; the peer median is $12M.
- Its year-over-year change of +375.0% is the highest of 2, against a peer median of +83.5%.
- Total liabilities amounts to 15.5% of total assets for LIXT, versus a peer median of 38.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $12M | +83.5% | +18.6% | 38.9% | |
| Mar 2026 | $1.69M | +375.0% | +64.8% | 15.5% | |
| Peer median (excluding LIXT) | $12M | +83.5% | +18.6% | 38.9% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.